This website contains information concerning Oncolytics Biotech Inc. (the “Company” or “we”) that may be useful to its customers, employees and shareholders as well as the general public. The Company makes no representations or warranties as to the accuracy of any information contained on this website. Further, the Company expressly disclaims any obligation to update or correct information contained on the website and explicitly disclaims any duty to do so. The Company assumes no liability or responsibility for any errors or omissions in the content of this website.
This website contains forward-looking information within the meaning of Canadian and United States securities laws. The forward-looking information provided includes the Company’s current expectations and / or forecasts of future events. Forward-looking information typically contains statements with words such as “anticipate,” “estimate,” expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning. In particular, these may include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expected progress in clinic trials, expenses, the outcome of contingencies such as legal proceedings, and financial results. From time to time, the Company also may provide oral or written forward-looking information in other materials released to the public.
Readers are cautioned not to place undue reliance on forward looking information and are informed that actual results may vary from forward-looking information. Any or all of the Company’s forward-looking information contained in this website and in any other public statements may turn out to be wrong.
With respect to forward-looking information, the Company has made assumptions regarding, among other things, that the Company: will be able to obtain sufficient and suitable financing to support operations, clinical trials and commercialization of products; will obtain favourable clinical trial results in the expected timeframe; will be able to adequately protect proprietary information and technology from competitors; and will be able to compete in targeted markets, given the impact of competitive products and pricing. Inaccurate assumptions made by the Company and known or unknown risks and uncertainties can affect the Company’s forward-looking information. Consequently, no forward-looking information can be guaranteed and actual results may differ materially from those expressed or implied by the Company’s forward-looking statements.
Some of the risks and factors that could cause actual results to differ materially from forward-looking information are the following: the risk that we may not be able to capitalize on partnering and acquisition opportunities; the risks relating to the uncertainties of the regulatory approval process; the risk that we may be unable to retain key personnel or maintain third party relationships, including relationships with key collaborators; our history of losses and the uncertainty of our future profitability; our ability to raise sufficient additional capital; the Company’s dependence on licensed technology; the safety and efficacy of REOLYSIN® as a cancer treatment; the success and timely completion of future clinical studies and trials; the Company’s ability to successfully commercialize REOLYSIN®; uncertainties related to the research and development of pharmaceuticals; uncertainties related to the regulatory process; general changes to the economic environment; identification of side effects after products are on the market; competition; lawsuits and exposure to product liability claims; ability to attract and retain key employees and consultants; and other factors contained under the heading “Risk Factors” in the Company’s most recent Annual Information Form, which is comprised of the Company’s Annual Report on Form 20-F. Forward-looking information contained on the website represents the Company’s judgment as of the date such information was posted on the website or is otherwise dated. The Company undertakes no obligation to publicly update any forward-looking information, whether as a result of new information, future events or otherwise.
Oncolytics Biotech Inc. respects your privacy. We do not collect any personally-identifiable information from this website other than the information you voluntarily supply on our Email Alert Form. We use this information to supply you with updates on Oncolytics’ business activities and, unless with your consent or as required by law, do not disclose your personal information to parties outside Oncolytics. This personal information is retained only as long as we need it in order to respond to you. Should you request it, we will remove any information about you from our files, except where we are legally obliged to retain that information. We take all reasonable steps to safeguard your personal information and use our best efforts to ensure that all individuals and organizations who work with us to create and update this website agree to safeguard your personal information in the same manner. Oncolytics will not sell or lease personally-identifiable information about you.
Our website may contain links to other websites. Oncolytics does not have any control over these linked websites and cannot be held responsible for the protection and privacy of any information that you provide while visiting them. Linked websites are not governed by the Oncolytics privacy statement. Users are encouraged to exercise caution and read the privacy statement applicable to the linked website in question.
Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More
Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More